Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research conducted at R.L. Jones and co-authors has provided new information about breast cancer
March 5th, 2009
"Accelerated (dose-dense) chemotherapy, in which the frequency of administration is increased without changing total dose or duration, may increase the efficacy of cancer chemotherapy. We performed a randomised Phase II study to assess the safety and relative toxicity of AC (doxorubicin; cyclophosphamide) vs E(epirubicin) C given by conventional or accelerated schedules as neoadjuvant or adjuvant chemotherapy for early breast cancer," researchers in London, the United Kingdom report. "Furthermore, the relative toxicity of doxorubicin and epirubicin remains uncertain. Patients were randomised to one of four arms; four courses of standard 3 weekly cyclophosphamide 600 mg...
Source: Women's Health Weekly (2009-03-05)
|
